Mosliciguat plus treprostinil for lung disease with pulmonary hypertension
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests a new medicine called mosliciguat combined with an inhaled treatment (treprostinil) for people who have both scarring lung disease (interstitial lung disease) and high blood pressure in the lungs. It aims to see if this combination can improve how well you feel and function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must already be using an inhaled medicine called treprostinil.
- You have scarring lung disease (interstitial lung disease), like idiopathic interstitial pneumonia, chronic hypersensitivity pneumonitis, or connective tissue disease related ILD.
- You have been diagnosed with pulmonary hypertension (high blood pressure in the lungs) confirmed by a heart catheterization test.
- You can walk at least 100 meters (about 1 city block) in 6 minutes.
- You do not have other types of lung or heart conditions that could cause similar symptoms.
- You have not started a new lung rehab program or had a worsening of your lung disease in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an inhaled medication called mosliciguat for people with pulmonary hypertension (high blood pressure in the lungs) caused by certain types of lung scarring. It may help improve your ability to exercise and manage symptoms.
This study tests an inhaled powder medication called TPIP (treprostinil palmitil inhalation powder) to see if it can improve symptoms and exercise ability in people who have both interstitial lung disease and pulmonary hypertension. The study will compare TPIP against a placebo (a dummy treatment without the active drug) to understand how well it works and if it is safe.
This program provides access to an inhaled medication called treprostinil for people who have pulmonary hypertension (high blood pressure in the lungs) related to interstitial lung disease (a type of lung scarring). The treatment aims to improve symptoms and quality of life.
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
This trial tests whether an inhaled medication called treprostinil (which helps open blood vessels in the lungs) can improve exercise ability in people who get high blood pressure in the lungs only during exercise. Participation involves taking the medication and doing exercise tests to see how well you do.
This trial tests an inhaled medicine that may help people with lung scarring or connective tissue disease who have high blood pressure in the lungs only during exercise. It aims to improve their ability to be active and reduce symptoms.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.